The current understanding of SGLT2 inhibitors (SGL2i) in heart failure with mid-range ejection fraction is primarily derived from retrospective analyses or subgroup assessments within broader heart failure trials that predominantly involve individuals with heart failure with reduced ejection fraction. Here, SLC5A2 is linked to heart failure.